

A photograph of two women embracing outdoors. The woman in the foreground has curly brown hair and is wearing a black off-the-shoulder top. A tattoo of the word 'Hope' in cursive is visible on her left shoulder. The woman behind her has blonde hair and is wearing a teal top. They are both smiling. The background is a blurred green landscape. A large purple circle is overlaid on the right side of the image, containing the title and subtitle. The bottom right corner features a purple triangle with the Target Ovarian Cancer logo.

Annual Report and Accounts

For the year ended 30 June 2019



TARGET
OVARIAN
CANCER

Contents

	PAGE
Chair and Chief Executive's statement	4
Report of the trustees:	
Objectives and activities	6
Our achievements	7
Looking forward	18
Governance, structure and management	20
Financial review	24
Statement of trustees' responsibilities	26
Independent auditor's report to the members of Target Ovarian Cancer	28
Financial statements:	
Statement of financial activities	30
Balance sheet	31
Statement of cash flows	32
Notes to the financial statements	33
Reference and administrative details	49

“I found out about Target Ovarian Cancer's Being Together days during a hospital appointment. I think they're really important for a lot of women to meet other people in the same boat, and to talk honestly. Days like this and other kinds of support are invaluable and having them has helped me to cope better with my diagnosis.”

Pam, Rochdale – diagnosed with ovarian cancer in 2006

Cover photo: Carol and Shauna chat at Being Together in Belfast.

This year's highlights:

We helped **931,269** people  learn the symptoms of ovarian cancer with our national campaigning.

 We have now funded **£1.25m** in ovarian cancer research projects across the UK.

Over **30,000** people used our award-winning ovarian cancer information every month. 

 This year began with a visit from Her Royal Highness The Duchess of Cornwall, to mark **10 years** of Target Ovarian Cancer. Her Royal Highness met women with ovarian cancer to talk about their experiences.

Chief Executive Annwen Jones was **awarded an OBE** for services to charity in the 2019 Queen's birthday honours.



A message from the Chair and Chief Executive

We are extremely proud to report that this has been another record year of growth at Target Ovarian Cancer. Spurred on by the momentum of our first national campaign to transform awareness of ovarian cancer – ‘It’s time to TAKE OVAR’ – we’ve seen a step change in our income, our reach and our impact.

We are firmly on track with our ambitious vision to double survival for women with ovarian cancer across all four nations of the UK. 11 women die every day from ovarian cancer and we will not stop until we achieve our goal. This year our income was £2.77m, a substantial 18 per cent increase, enabling us to do so much more to transform the future for women with ovarian cancer.

The year began with a very special royal visit from Her Royal Highness The Duchess of Cornwall to mark our 10th anniversary. Her Royal Highness met women with ovarian cancer and our researchers at the Beatson Cancer Centre in Glasgow, shining a light on this devastating disease. Buoyed by the visit, we pushed forward our programmes to transform diagnosis, treatment and support for women diagnosed with ovarian cancer:

We’ve been at the forefront of early diagnosis in ovarian cancer for a decade. This year we received one of the largest grants in our history from the Peter Sowerby Foundation, and work has begun on a sector-first initiative to end the postcode lottery in early diagnosis, giving every woman the best possible chance of successful treatment.

We’re also playing a leading role in harnessing the power of groundbreaking immunotherapy research to transform ovarian cancer treatment by funding the work of Dr Martin Miller at the University of Cambridge. His work will build on Nobel Prize-winning research to unlock the power of the immune system.

We believe fundamentally that every woman diagnosed with ovarian cancer should receive the right support at the right time, in the way that is right for her. We’re so grateful to our supporters for helping us to fund the most comprehensive ovarian cancer support service in the UK. Our flagship nurse-led Support Line continues to grow with a third more questions and queries than last year. These come directly from the people that matter the most – women with ovarian cancer.

We should all be rightly proud of the transformational progress that we are making but we also know there is still so much more to do. Together we have created a powerful and growing movement for change and we will not stop until every woman diagnosed with ovarian cancer has the best possible chance of survival.

We want to extend our profound and heartfelt thanks to everyone who has helped us achieve so much this year. Together, we **are** saving lives.



Emma Kane

Emma Kane
Chair



Annwen Jones

Annwen Jones OBE
Chief Executive



HRH The Duchess of Cornwall marks 10 years of Target Ovarian Cancer

Report of the trustees

Objectives and activities

Target Ovarian Cancer is the UK's leading ovarian cancer charity. In order to transform the futures of everyone affected by ovarian cancer, we work to:

- improve **early diagnosis**
- fund life-saving **research**
- provide much-needed **support** to women with ovarian cancer

We are the only charity fighting ovarian cancer on all three of these fronts, across all four nations of the UK.

Our gamechanging campaign, 'It's time to TAKE OVAR', is transforming the futures of more than 25,000 women in the UK who are living with ovarian cancer, and thousands more who are yet to be diagnosed.

Our achievements

“Yours is the... best of all the websites; the guides feel like a friend putting their arm around you and giving you a big hug.”

Anon, accessed support from Target Ovarian Cancer this year

Target Ovarian Cancer's plans for 2018-2019

Expand our GP awareness programme, training more GPs to spot ovarian cancer and ensuring more women are diagnosed earlier.

✓

Fund at least one new ovarian cancer research grant, furthering our bold ambition of transforming treatments for women with ovarian cancer.

✓

Expand the reach of our nurse-led Support Line, directly supporting even more women with ovarian cancer and those worried about the symptoms of the disease.

✓

Expand our one-stop shop for ovarian cancer support by enabling more women to attend our unique ovarian cancer support events and ensuring our award-winning ovarian cancer guides reach the people who need them.

✓

Deliver Target Ovarian Cancer's Ask the Experts Conference, the UK's biggest ovarian cancer conference, bringing together women with ovarian cancer and health experts.

✓

Work closely with health professionals, particularly Clinical Nurse Specialists, to deliver the high standard of care that women need. The Clinical Care Standard was launched in July 19.

Launched
July 2019

Grow our ovarian cancer campaigns network.

✓

Implement the next phase of 'It's time to TAKE OVAR', our integrated campaign.

✓

Secure an ovarian cancer clinical audit for England to tackle the postcode lottery in diagnosis and treatment of ovarian cancer.

Audit pilot
commenced

Improving early diagnosis

Awareness of ovarian cancer is alarmingly low, both among women and GPs. Two thirds of women are diagnosed once the cancer has already spread and 20 per cent are too ill to treat by the time they are diagnosed.^{1,2}

It's time to TAKE OVAR: Together we can make sure women are diagnosed at the earliest possible stage.

- We launched a project to end the postcode lottery in early diagnosis of ovarian cancer. Thanks to transformational funding from the Peter Sowerby Foundation, the sector-first initiative will tackle the problem of early diagnosis in a radically new way.
- The number of healthcare professionals completing our ovarian cancer education modules doubled, with nearly 9,000 new GPs and GP nurses trained during the year. Our modules are accredited by the Royal College of General Practitioners and the Royal College of Nursing.
- An expansion of our free GP toolkit made it possible for us to reach even more healthcare professionals. Using our toolkit, GPs can access new factsheets on diagnostic tests and genetics in ovarian cancer, plus symptoms information and awareness raising materials.
- We reached over 6,000 healthcare professionals at GP live events, increasing knowledge of ovarian cancer face-to-face and through talks and seminars.
- The Target Ovarian Cancer and Royal College of Obstetricians and Gynaecologists' joint essay prize helps to educate the specialist clinicians of tomorrow. This year's prizes were awarded to students from Newcastle University and the University of Birmingham.
- A core priority in early diagnosis is to raise awareness of the symptoms of ovarian cancer. Our partnerships with Neighbours, Stylist Magazine and The Sun's Fabulous magazine helped us reach millions of people in new audiences, and our work during Ovarian Cancer Awareness Month reached over 900,000 people.

“The earlier ovarian cancer is picked up, the more effective the treatment is. It's that simple. We know there is still a long way to go, but we are seeing more women survive ovarian cancer than ever before. It's very important for women to know their own bodies and I would encourage them to discuss any changes they're concerned about with a healthcare professional as soon as they can.”

Dr Alison Wint GP, Clinical Lead for Cancer South Gloucester CCG and member of Target Ovarian Cancer's GP Advisory Board



Dr Sharon Tate works face-to-face with GPs so they can diagnose ovarian cancer as early as possible.

¹ National Cancer Registration and Analysis Service (2019) Stage breakdown by CCG 2017. Available at: www.ncin.org.uk/publications/survival_by_stage [Accessed 7 August 2019]

² Target Ovarian Cancer (2018) Data briefing on ovarian cancer. Available at: www.targetovariancancer.org.uk/getdataout [Accessed 7 August 2019]

Finding new treatments

More women die from ovarian cancer each year than all other gynaecological cancers combined, and yet investment in ovarian cancer research has dropped drastically in the last decade.³

It's time to TAKE OVAR: Together we can fund life-saving research to transform treatments and double survival rates.

- Target Ovarian Cancer's distinctive UK-wide medical research programme continues, with three projects at the University of Manchester, University of Surrey and the University of Glasgow tackling major challenges in ovarian cancer treatment and care.
- Target Ovarian Cancer's newest research project with Dr Martin Miller at the University of Cambridge could revolutionise how we treat ovarian cancer. It will build on Nobel Prize-winning research to unlock the power of the immune system.
- Building on success in England, our campaign for access to PARP inhibitor drug niraparib (Zejula®) was successful in Scotland and Northern Ireland, making it the first in this new generation of ovarian cancer drugs to be available across the UK to a larger group of women without a BRCA mutation.
- A record 9,000 people visited our Ovarian Cancer Clinical Trials Information Centre during the year. Giving details of every live UK ovarian cancer clinical trial means more women will benefit from better access to trials and treatment.
- Access to clinical trials for new drugs still depends on where you live. We continued our campaign for change, highlighting the 11-fold difference between the best and worst performing regions at the British Gynaecological Cancer Society's annual conference.
- Early diagnosis research by Dr Elizabeth Moore at the University of Cambridge has found more accurate, non-invasive ways to diagnose high-grade serous ovarian cancer. Dr Moore's research was jointly funded with the Medical Research Council (MRC) and early findings were published in *Science Translational Medicine*.

“Target Ovarian Cancer works to change lives both at home and on a world stage. Their work on improving treatments and care for women with ovarian cancer is crucial and very much needed.”

Professor Sudha Sundar, President of the British Gynaecological Cancer Society and Consultant in Gynaecological Oncology at the Pan Birmingham Gynaecological Cancer Centre.



Dr Aula Ammar works in her lab in Glasgow.

³ Cancer Research UK website. Available at: www.cancerresearchuk.org/health-professional/cancer-statistics [Accessed 2 August 2019]

Providing support for women

Less than half of gynaecological cancer nurses say there are enough nurses in their centre to fully support all women in their care, and three quarters of women with ovarian cancer say they do not get the support they need.

It's time to TAKE OVAR: Together we can make sure every woman receives the right support at the right time, in the way that is right for her.

- We supported 30,000 people every month with our ovarian cancer information - 25 per cent more than last year.
- We never stop evolving and improving our support for women. This year we launched a much-needed guide on a little-discussed topic, *Ovarian cancer and stomas*. We also created podcasts on difficult subjects ranging from sex and intimacy to living well with ovarian cancer at Christmas.
- Two thirds of women who came to our face-to-face support events this year had never met anyone else with ovarian cancer. After attending, 96 per cent told us they had shared their story with other women on the day, lessening the isolation they had felt before.
- Our flagship Ask the Experts Conference showcased the latest developments in research, treatment and care. 92 per cent of people felt they knew more about ovarian cancer diagnosis and treatment after hearing from leading UK clinicians on the day.
- A record number of people called Target Ovarian Cancer's unique nurse-led Support Line this year. Our nurses answered 35 per cent more questions and queries than last year, averaging 72 per month.
- We developed the first ever **ovarian cancer care standard**, building on the experience of Clinical Nurse Specialists. The standard will help nurses and clinicians give the best possible care, supporting women to live well with ovarian cancer from the moment they are diagnosed.
- We attended eight nursing events across the UK and regularly updated our online nursing hub to provide best practice and support. Reaching more nurses is crucial to improving ovarian cancer care and support.

“My care, my future is one of the best booklets on a medical topic I have ever read, particularly as it is for a group of patients who may not have the information they need. It is extremely well done with truth and a genuine sharing of experience and information.”

Dr Nansi-Wynne Evans GP, Powys, British Medical Association Patient Information Awards judge

Lauren reads through one of our award-winning ovarian cancer guides.

Our campaigning

11 women die every day from ovarian cancer, and ovarian cancer faces chronic underfunding compared with other cancers.

It's time to TAKE OVAR: Together we are campaigning to accelerate change and transform the futures of more than 25,000 women in the UK who are living with ovarian cancer, and thousands more who are yet to be diagnosed.

- We revealed the shocking statistic that one in five women is too sick to treat by the time they are diagnosed, in an in-depth data briefing. This work was in partnership with Public Health England's Get Data Out team.
- A second data briefing focused on the postcode lottery in early diagnosis. Thirty percentage points stand between the best and worst performing areas of the UK and over 400 campaigners called on the Prime Minister for change in the wake of the news.
- We launched the ovarian cancer audit feasibility pilot with partners including the National Cancer Registration and Analysis Service, British Gynaecological Cancer Society and Ovarian Cancer Action. The pilot is a major step towards delivering real improvements in NHS treatment.
- Target Ovarian Cancer has helped more people than ever get involved and push ovarian cancer up the political agenda. Our campaigners now number over 700 and they took action 1,711 times this year.
- Target Ovarian Cancer engaged with all 650 UK MPs at least once, whether briefing them for a debate, tabling parliamentary questions, or asking them to be a Teal Hero and raise awareness for Ovarian Cancer Awareness Month.
- Ovarian cancer came top of the parliamentary agenda when Lee Rowley MP secured a parliamentary debate in Westminster Hall. Our campaigners emailed 400 MPs about the debate, spreading awareness right across parliament.
- Thanks to our campaigning and evidence, ovarian cancer is now a high priority in NHS England's new Long Term Plan. The Plan includes a commitment to improve specialist treatment, starting with ovarian cancer.

“Public Health England is proud to partner with Target Ovarian Cancer on projects such as Get Data Out and the ovarian cancer audit feasibility pilot. Projects like these help further develop our shared understanding of ovarian cancer diagnosis and treatment and in turn drive work to improve outcomes for women with ovarian cancer.”

Lucy Elliss-Brookes, Head of Cancer Analysis, National Cancer Registration and Analysis Service at Public Health England



Together with our campaigners we are transforming the future for women with ovarian cancer.

Our fundraising

This year was a record year for Target Ovarian Cancer. Building on the successes of previous years, we have seen a step change in our income, which is now £2.77m, an 18 per cent increase, enabling us to do much more to transform the future for women with ovarian cancer. Thank you to everyone who has helped us reach this milestone.

We saw a record increase in donations and fundraising from individuals, whether in memory of a loved one, through events, or dedicated friends and family working to raise money in their local community. We saw an incredible increase in income from donated services, primarily advertising space, for which we are profoundly grateful.

Our flagship event The Ovarian Cancer Walk|Run had over 400 participants, raising more than £130,000, and our 2019 London Marathon team had a record 25 runners who raised almost £70,000. We'd like to thank all participants for putting in a tremendous effort, both in the months leading up to the race and on the day. Thank you also to Coutts for hosting our post-marathon event.

This year was our biggest ever for legacy income. We are very grateful for the gifts received this year from the estates of: Mary Andrews, Heather Bell, Priscilla Kathleen Boswell, Dorothy Burns, Bridget Carey, Madeline Anne Duncan, Rebecca Jane Valentine and Coral Wiggins. We would also like to remember Lynn Nelson, who left us the single largest gift we've ever received from an estate, an

amazing £174,000. We would also like to thank Richard Roberts for generously hosting a reception for supporters at Durham Cathedral.

We'd like to extend a special thanks to The Peter Sowerby Foundation for their transformational grant of over £300,000, and to the Ardeola Charitable Trust for the completion of their Matched Research Fund pledge and for continuing to support our core costs. We were also thrilled to receive a National Lottery Community Fund Awards for All grant towards our event, Being Together in Belfast.

Finally, thank you to our committed fundraisers and volunteers, including the members of the 360 Club and Research Giving Circle, those who attended our fundraising dinner at the Science Museum, and Travers Smith LLP for hosting our research briefing in spring 2019. Thank you to everyone who helped TAKE OVARIAN during our largest ever Ovarian Cancer Awareness Month in March. You took part in hundreds of activities and challenges and raised almost £75,000.

Thank you for your incredible support.



“Mum’s GP said that it could be IBS and that delayed her diagnosis. When she passed away, supporting and raising funds for Target Ovarian Cancer really helped me. It has given me a focus. I think how Mum would have felt and it fills me with pride.”

Rob, whose mum Jean died from ovarian cancer

Seema and her family take part in The Ovarian Cancer Walk|Run in memory of mum Savarn Lata.

Looking forward

Target Ovarian Cancer has been a catalyst for change across the ovarian cancer landscape in the UK, leading systemic change in awareness, diagnosis, treatment and support.

In 2019-2020, we will build on our record achievements to get closer to our vision of doubling survival from ovarian cancer by 2050.

Complete the first phase of our transformational project to end the postcode lottery in early diagnosis of ovarian cancer.

Fund at least one new ovarian cancer research grant through our gold-standard national programme.

Directly support even more women with ovarian cancer through our nurse-led Support Line.

Expand our GP awareness programme, training more healthcare professionals to spot ovarian cancer earlier.

Roll out the ovarian cancer care standard, supporting nurses and helping women to live well with ovarian cancer from the moment they are diagnosed.

Publish the first findings from the ovarian cancer audit feasibility pilot.

Expand our information, support and signposting service so that it remains the most comprehensive in the UK.

Implement the next phase of 'It's time to TAKE OVAR', our integrated campaign.

Governance, structure and management

Legal entity

Target Ovarian Cancer is a company limited by guarantee registered as a company in England and Wales on 13 June 2008. It was registered as a charity in England and Wales on 17 July 2008 and in Scotland on 6 February 2012. The governing document is the Memorandum and Articles of Association, dated 13 June 2008. New Articles of Association were adopted by special resolution, dated 29 December 2011, and were amended by special resolution, dated 21 November 2013 and 14 April 2016.

Charitable objects

The objects of the charity are the relief of sickness and the advancement of health for the benefit of the public, in particular, among women who have or are at risk of developing ovarian cancer or other gynaecological diseases by: the promotion of research into the causes, prevention, detection, treatment and cure of ovarian cancer and other gynaecological diseases and their effects and the dissemination of the useful results of such research; relief of suffering among women affected by ovarian cancer and other gynaecological diseases, their families and dependents, through the provision of support and information; and the education of the public on issues relating to ovarian cancer and other gynaecological diseases.

Trustees

Emma Kane, Chair, is Chief Executive of Newgate

Communications Ltd and Deputy CEO of SEC Newgate S.p.A., Joint CEO of Porta Communications plc, Chair of the Barbican Centre Trust, and a trustee of Nightingale Hammerson. Emma's stepchildren's mother, Heather Ash, died from ovarian cancer at the age of 52 in 2007.

Joanna Barker MBE

Joanna founded Target Ovarian Cancer in 2008, and has over thirty years' experience in business and finance. Joanna's mother and sister died from ovarian cancer in 2005. She is a lay member of the Council of the University of Durham, which awarded her an honorary doctorate (D.Litt) in 2012. In 2014 she was awarded an MBE in the Queen's birthday honours.

Margaret Chamberlain is a solicitor and consultant at the London City law firm Travers Smith LLP, where she was a partner for 25 years, and a trustee of Parkinson's UK. Margaret has lost two beloved friends to ovarian cancer and this drives her to support Target Ovarian Cancer's work on early diagnosis, more research and support for women with ovarian cancer.

Alexandra Cran-McGreehin is a senior civil servant at the Department for Environment, Food and Rural Affairs. She has previously worked in HM Treasury, the Department for Education and as Head of Secretariat for the Independent Commission for Aid Impact. Alexandra's mother, Penelope Cran, died from ovarian cancer in 2014.

Andrew Harrison is Head of Investor Relations at Silverfleet

Capital, a leading European private equity firm specialising in mid-market buyouts. Andrew has been a longstanding supporter and fundraiser for Target Ovarian Cancer since his mother-in-law died suddenly from ovarian cancer in 2010.

Shona Spence, Treasurer, is an experienced Chief Financial Officer with over 25 years' experience working in the financial services sector. Shona is a member of the audit and risk committee of an age-related charity, a Fellow of the Institute of Chartered Accountants in England and Wales and holds a BSc (Hons) degree in Immunology from London University.

Trustees: appointment and induction

Target Ovarian Cancer recognises that a robust, independent and effective Board of Trustees is essential if the charity is to achieve its objects; that the Board must have available to it all of the knowledge and skills required to govern the charity; and that individual trustees must have sufficient knowledge, both of trusteeship in general and of the charity's activities to enable them to carry out their role. New trustees are recruited through advertisements in the media and a range of networks in line with the charity's Recruitment of Trustees policy and Equal Opportunities policy. They are appointed by the Board and formally elected at a general meeting of the members. Trustees are appointed for a three-year term, after which they are eligible for re-election for a further three-year term.

All new trustees receive an induction session, arranged and co-ordinated by the Chief Executive, usually within one month of their appointment. During this session, new trustees are provided with a trustee induction pack that includes the charity's governing document, business plan, core governance policies, financial statements and minutes of previous trustee meetings as well as Charity Commission guidance on effective non-profit governance.

Trustees receive no remuneration for their time and can claim only documented expenses incurred in carrying out their duties in line with the trustee expenses policy. No expenses were claimed in the year ending 30 June 2019 [2018: £0].

Charity governance code

Target Ovarian Cancer is committed to embedding the highest standards of governance within the Charity. In 2018-19 the Board adopted the Charity Governance Code and undertook an internal review, using the Code's diagnostic toolkit, to help identify priority areas for improvement. The Board was satisfied that overall its policies and practices conformed to the best practices of governance set out in the Code. It agreed to review and, if needed, update the following areas in 2019-20: (i) the Statement of Delegated Responsibility; and (ii) the Conflict of Interests Policy. It was also agreed that a Board Evaluation will be undertaken during the year ahead.

Organisational structure

The Board of Trustees is responsible for setting Target Ovarian Cancer's strategic objectives, the strategy to achieve them and the major policies of the charity. It is responsible for directing the executive staff, monitoring performance and for identifying and managing the major risks facing the charity. The Board meets five times a year.

The Chief Executive supports and advises the Board in its activities and, in line with the charity's Statement of Delegated Responsibility, is, subject to executive limitations, responsible and fully accountable for achieving strategic objectives including annual key performance indicators set by the Board.

The charity pays its staff market rate salaries, which are determined by benchmarking across the sector and taking into consideration any specialist skills. The salary budget is approved by the Board of Trustees as part of the annual budget setting process.

The Chief Executive is supported by an expert team of staff. The total number of staff employed at 30 June 2019 was 28 (2018: 27).

Volunteers

The trustees recognise the extremely valuable contribution made by volunteers and wish to place on record their grateful thanks for that commitment. These include the many women living with ovarian cancer; others who undertake fundraising, networking, campaigning and



media work on behalf of the charity and who inform the development of our services; members of Target Ovarian Cancer’s Scientific Advisory Board, GP Advisory Board, Clinical Advisory Panel and Digital Advisory Panel; the health professionals who support us producing our information and putting on our events; and those who have given pro bono advice and support across a broad range of activities. No amounts are included in the financial statements to reflect the value of work undertaken by volunteers.

Staff

The trustees are grateful to all members of staff for the outstanding work that they do on behalf of women with ovarian cancer. Target Ovarian Cancer seeks to be an employer of choice and reviews on an annual basis the level of remuneration and other benefits awarded to staff. All staff are appointed at market rate salaries, and salary levels are benchmarked at regular intervals with the external market.

Risk assessment

The trustees have established a risk assessment process through which they identify the major foreseeable risks faced by the organisation, assess their likely impact and, where appropriate, implement measures to mitigate these risks. In our risk map, the

principal risks are categorised under the headings Governance, Operational, Financial, External and Compliance.

The most significant risks to the charity have been identified as:

- 1) The ability to meet income targets to support growth

This has been mitigated against through investment in fundraising, a detailed fundraising strategy and ongoing monitoring of progress.

- 2) The ability to recruit key staff to deliver the 2017-20 business plan

Salaries are regularly benchmarked to market rates and additional non-pay benefits are publicised to attract high quality staff. Specialist agencies are used to recruit key skilled staff with a robust interview and selection process and a detailed induction.

The trustees have reviewed the major risks to which Target Ovarian Cancer is exposed, in the areas where it operates and the activities it undertakes, and are satisfied that appropriate actions have been taken and systems have been established to monitor and mitigate those risks.

Grant making policy

Target Ovarian Cancer launched its unique national ovarian cancer

research programme in 2012. We aim to find and fund world-class research for the benefit of women with ovarian cancer, and our funding is open to researchers across the UK. Our gold-standard scientific review process ensures that we only fund the best doctors and researchers in hospitals and universities across the UK. The trustees award grants based on the recommendations of our Scientific Advisory Board, which considers further opinions from national and international experts in the field as well as patient representatives. Our membership of the Association of Medical Research Charities is an important mark of approval of the high quality of our peer review process.

Public benefit

From 1 April 2008 the Charities Act requires every charity to meet the legal requirement that its aims are for the public benefit. The Charity Commission in its ‘Charities and public benefit’ guidance states that there are two key principles to be met in order to show that an organisation’s aims are for the public benefit: firstly, there must be an identifiable benefit and secondly, that the benefit must be to the public or a section of the public. The trustees are satisfied that the aims and objectives of the charity, and

the activities reported on in this Annual Report to achieve those aims, meet these principles.

Fundraising standards

The charity undertakes fundraising activity via direct mail, treks, fundraising events, sponsored events, gala dinners and other such activities. The trustees abide by the Fundraising Code of Practice set by Fundraising Regulator in overseeing the fundraising activities of Target Ovarian Cancer and any third parties fundraising on the charity’s behalf. They also follow the Office of the Scottish Charity Regulator guidance covering Scottish charity law in relation to fundraising and charity trustee duties.

During the year to 30 June 2019, the charity worked with an individual fundraising consultant on a short term basis in delivering fundraising activity. She adhered to the Fundraising Code of Practice and our policies and procedures regarding privacy and the treatment of supporters and donors. We monitored her activities on a regular basis to ensure compliance.

We train our fundraising staff and volunteers to reinforce our fundraising ethics, policies and procedures. Our volunteers are

supervised in their activities by charity staff to ensure compliance. One complaint regarding a minor administrative issue was received in the period to 30 June 2019. It was resolved according to our complaints procedure.

Target Ovarian Cancer’s fundraising abides by the four key principles of the Institute of Fundraising’s *Treating donors fairly* policy, which are:

- Respect
- Fairness
- Responsive
- Accountable

We follow the Institute of Fundraising guidance if we suspect that a donor lacks the capacity to make a decision about the donation. We continued to review and implement our safeguarding policy, including safeguarding vulnerable donors. We have a lead officer for safeguarding and a safeguarding panel to review any cases where a vulnerable donor is suspected.

Working with others

Target Ovarian Cancer is committed to working in collaboration with others who share an interest in improving outcomes for women with ovarian cancer. The charity will not duplicate work that is

already meeting the needs of women with ovarian cancer.

In addition to being a co-founder of the Ovarian Cancer Awareness Month charity portal – www.ocam.org.uk – Target Ovarian Cancer works with the following organisations: All-Party Parliamentary Group on Ovarian Cancer (we provide the secretariat); Association of Medical Research Charities; British Gynaecological Cancer Society; Medical Research Council; National Cancer Registration and Analysis Service; National Cancer Research Institute; National Institute of Health and Care Excellence; National Institute for Health Research; National Forum of Gynaecological Oncology Nurses; NHS England; Public Health England; Royal College of General Practitioners; Royal College of Obstetricians and Gynaecologists; Royal College of Nursing; Scottish Cancer Coalition; Scottish Medicines Consortium; Wales Cancer Alliance; Cancer 52; Colostomy UK; The Eve Appeal; Hospice UK; Jo’s Cervical Cancer Trust; Macmillan Cancer Support; Maggie’s Cancer Centres; Ovacom; Ovarian Cancer Action; Pancreatic Cancer UK.

Target Ovarian Cancer is a co-founder of the World Ovarian Cancer Coalition and World Ovarian Cancer Day.

Financial review

Financial activities

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the charity’s governing documents, the Charities Act 2011 and *Accounting and Reporting by Charities: Statement of Recommended Practice* applicable to charities preparing their accounts in accordance with the Financial Reporting Standard in the UK and Republic of Ireland and published on 16 July 2014.

Income

The charity increased its income by 18 per cent to £2,768,937 [2018: £2,355,847]. This substantial growth reflects a 17 per cent increase in general donations to £1,318,853 [2018: £1,127,172] and a 37 per cent increase in donated services for charitable activities to £555,707 [2018: £405,703], supporting the charity to further increase its reach. Gifts from legacies increased by 28 per cent to £231,541 [2018: £181,170].

During 2016-17, Target Ovarian Cancer invested in a comprehensive strategic review to determine the future direction of the charity. Our goal was to develop a strategy to drive a step change in improving the future for women with ovarian cancer, as incremental change will not deliver the transformation in outcomes that needs to be achieved. Our vision to double ovarian cancer survival by 2050, and the investment required to achieve this target, are a direct outcome of the conclusions of this strategic review.

2018-19 is the second year of the current business plan. The strategic priority for this financial year was to continue increasing our income and to implement Phase II of the ‘It’s time to TAKE OVAR’ integrated campaign, focusing on increasing financial returns and broadening our reach. Our gifts in kind income, which demonstrates the growth in awareness of the charity, also increased significantly thanks to the generous pro bono support of our corporate and media partners. A full breakdown of funding sources is given in Note 3 to the financial statements.

The trustees wish to acknowledge all donors and volunteers for their invaluable support during the past year.

Expenditure

Expenditure increased by 12 per cent overall to £2,396,850 [2018: £2,135,928] following investment in both fundraising and the ‘It’s time to TAKE OVAR’ integrated campaign to deliver the 2018-19 objectives of the Business Plan.

Our expenditure on research £303,984 [2018: £261,375] increased by 17 per cent, in part due to the award of a new research grant to Dr Martin Miller at the University of Cambridge during the year.

Expenditure on earlier diagnosis £859,531 [2018: £672,158] and supportive services £511,623 [2018: £471,899] continues to reflect the shift in donated services seen in 2017, predominantly advertising, for earlier diagnosis rather than supportive services.

The overall surplus for the year of £372,087 [2018: £219,919] reflects the continued success of the planned investment in fundraising and the ‘It’s time to TAKE OVAR’ campaign.

Reserves policy

The Board of Trustees has formulated a policy to maintain the general fund reserve level at a minimum while ensuring that it has sufficient funds to cover existing project commitments. This was set for 2019 at £362,575, based on three months of budgeted salary expenditure and six months of budgeted rent and support costs.

The charity significantly exceeded its unrestricted reserves target of £362,575 by £306,787 or 84 per cent in 2019. To support achievement of our vision of doubling ovarian cancer survival by 2050, the charity had previously decided to invest a generous charitable bequest from Mr Gordon Luton of £157,350 in legacy fundraising over a three year period, and in the integrated campaign in 2018-19. The amount designated in the reserves for 2019-20 is £42,050.

Schedule of spend	2019-2020	2018-2019	2017-2018	Total
	£	£	£	£
Designation 1: Legacy fundraising	42,050	40,600	32,700	115,350
Designation 2: Integrated campaign	-	42,400	-	42,400
	42,050	83,000	32,700	157,750

Restricted funds arise when conditions are imposed by the donors or by the specific terms of the appeal, and can only be spent on the activities specified. At 30 June 2019 restricted funds amounted to £593,505 [2018: £423,318] representing funding for the Target Ovarian Cancer research programme.

Total funds held at June 30 2019 were £1,262,867 [2018: £890,780]. The charity invested in the growth of its charitable activities in 2018-19; our surplus and reserves will be reduced in 2019-20 as the surplus funds are applied to furthering our mission to transform survival in ovarian cancer.

Investment policy

The charity aims to secure as a matter of urgency the earliest possible improvements in survival and quality of life for women with ovarian cancer so surplus funds are not committed to long-term investment but rather are deposited in savings accounts, so that they are readily available.

Going concern

The trustees are able to confirm that they are of the opinion there are no material uncertainties related to events or conditions that may cast significant doubt over the ability of the charity to continue as a going concern.

Statement of trustees' responsibilities in respect of the trustees' annual report and the financial statements

The trustees are responsible for preparing the trustees' annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the trustees to prepare financial statements for each financial year. Under that law they are required to prepare the financial statements in accordance with UK accounting standards and applicable law (UK Generally Accepted Accounting Practice), including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the excess of income over expenditure for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- assess the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and
- use the going concern basis of accounting unless they either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions, disclose with reasonable accuracy at any time the financial position of the charitable company, and enable them to ensure that the financial statements comply with the Companies Act 2006. They are responsible for such internal control as they

determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the charitable company and to prevent and detect fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the UK governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

So far as each of the trustees is aware at the time the report is approved:

- there is no relevant audit information of which the company is unaware;
- they have taken all the steps that they ought to have taken as a director to make the auditors aware of that information.

The Trustee's Report has been prepared in accordance with the special provisions relating to the small companies regime within Part 15 of the Companies Act 2006.

Approved by the trustees on 1 October 2019 and signed on their behalf by:



Emma Kane
Chair, Board of Trustees



Independent auditor's report to the members of Target Ovarian Cancer

Opinion

We have audited the financial statements of Target Ovarian Cancer for the year ended 30 June 2019 which comprise the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 30 June 2019 and of the charitable company's net movement in funds, including the income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006 and the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs

(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of trustees for the financial statements

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charitable company's ability to continue to adopt

the going concern basis of accounting for a period of at least 12 months from the date when the financial statements are authorised for issue.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Trustees' Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report (which includes the strategic report and the directors' report prepared for the purposes of company law) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and the directors' report included within the Trustees' Report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report (which incorporates the strategic report and the directors' report).

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charity Accounts (Scotland) Regulations (as amended) require us to report to you if, in our opinion:

- adequate accounting records have not been kept by the charitable company; or
- the charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or

- the trustees were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemptions in preparing the trustees' report and from the requirement to prepare a strategic report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Kathryn Burton
(Senior Statutory Auditor)

For and on behalf of
Haysmacintyre LLP,
Statutory Auditors

10 Queen Street Place
London
EC4R 1AG

Statement of financial activities

(incorporating an income and expenditure account)

For the year ended 30 June 2019

Charity Number: 1125038
Company Number: 6619981

	Notes	Unrestricted £	Restricted £	2019 £	2018 £
Income from:					
Donations and legacies	3	2,323,648	441,966	2,765,614	2,355,308
Investment income		3,323	-	3,323	539
Total income		2,326,971	441,966	2,768,937	2,355,847
Expenditure on:					
Raising funds		721,802	-	721,802	730,496
<i>Charitable activities</i>					
Research		137,815	166,079	303,894	261,375
Earlier diagnosis		829,043	30,488	859,531	672,158
Supportive services		436,411	75,212	511,623	471,899
Total expenditure	4	2,125,071	271,779	2,396,850	2,135,928
Net income for the year	5	201,900	170,187	372,087	219,919
Funds brought forward					
		467,462	423,318	890,780	670,861
Total funds carried forward		669,362	593,505	1,262,867	890,780

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in note 14 to the financial statements. The comparative SOFA from 2018 can be seen in Note 22.

Balance sheet

As at 30 June 2019

	Notes	£	2019 £	£	2018 £
Fixed assets					
Tangible fixed assets	9		12,135		18,448
Current assets					
Debtors	10	199,213		54,696	
Cash at bank and in hand	11	1,424,966		1,224,896	
			1,624,179	1,279,592	
Liabilities					
Creditors: amounts due within one year	12	(373,447)		(407,260)	
Net current assets			1,250,732		872,332
Total assets less current liabilities			1,262,867		890,780
Net assets	14		1,262,867		890,780
Funds					
Restricted funds	14		593,505		423,318
Unrestricted funds					
Designated funds	15	42,050		125,050	
General funds		627,312		342,412	
			669,362	467,462	
Total charity funds			1,262,867		890,780

Approved by the trustees on 1 October 2019 and signed on their behalf by



Emma Kane
Chair



Shona Spence
Treasurer

The notes on page 33-48 form part of the financial statements.

Statement of cash flows

For year ending 30 June 2019

	Note	2019 £	2018 £
Cash provided by (used in) operating activities	19	198,285	191,172
Cash flows from investing activities			
Dividends, interest and rents from investment		3,323	539
Purchase of property, plant and equipment		(1,538)	(20,153)
Cash provided by (used in) investing activities		1,785	(19,614)
Change in cash and cash equivalents in the reporting period		200,070	171,558
Cash and cash equivalents at the beginning of the year	20	1,224,897	1,053,339
Cash and cash equivalents at end of year		1,424,966	1,224,896

Notes to the financial statements

For the year ended 30 June 2019

1. Accounting policies

- a) The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. Target Ovarian Cancer meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

b) The trustees are of the view that there are no material uncertainties regarding the charity's ability to continue as a going concern and therefore the assessment of the trustees is that the charity is a going concern.

c) Preparation of the accounts requires trustees and management to make significant judgement and estimates. Judgment and estimates have been applied in the accounts in the following areas:

 - Estimating the probability of the receipt of legacy income and estimating the amount to be received
 - Entitlement to income on multi-year grants received
 - Estimating the liability of any multi-year grants payable
 - Estimating the useful economic life of tangible fixed assets
 - Estimating dilapidation costs on cessation of the premises lease

d) Restricted funds are to be used for specific purposes as laid down by the donor. Expenditure which meets these criteria is charged to the fund. Transfers between restricted and unrestricted funds are only made
- when written instructions have been received from the original donor.

e) Unrestricted funds are donations and other income is received or generated for the charitable purposes.

f) Donations and legacies are recognised in the financial statements when the charity is entitled to the income, it is more probable than not that the charity will receive the income, and the amount can be measured reliably.

g) Donated services are only included in income (with an equivalent amount in expenditure) where the benefit to the charity is reasonably quantifiable, measurable and material. The value placed on these resources is the estimated value to the charity of the service or facility received. The value of any voluntary help received is not included in the accounts but is described in the trustees' annual report.

h) Raising funds relates to the costs incurred by the charitable company in encouraging donations, as well as the cost of any activities with a fundraising and publicity purpose.

i) Expenditure is recognised in the period in which it is incurred. Expenditure includes attributable VAT which cannot be recovered.

j) Grants are recognised to the extent that a liability is incurred from a constructive or a legal obligation.

k) Support costs are those costs which do not in themselves constitute a charitable or fundraising activity but are necessary to support these activities. They will include central office functions such as finance, HR and general management.

l) Expenditure is allocated to the particular activity where the cost relates directly to that activity. Support costs are re-allocated to each of the activities based on direct staff costs.

m) Governance costs form part of support costs and are the costs associated with the governance arrangements of the charity. These costs are associated with constitutional
- and statutory requirements and include any costs associated with the strategic management of the charity's activities.

n) Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. A full year's depreciation is charged in the year of acquisition. The depreciation rates in use are as follows:

<i>Furniture, fixtures and office equipment</i>	<i>3 years</i>
<i>Digital assets</i>	<i>3 years</i>
<i>Website upgrade</i>	<i>5 years</i>

o) Items of equipment are capitalised where the purchase price exceeds £500. Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate their carrying value may exceed their net realisable value and value in use.

p) The charity pays 5 per cent employer contribution to the private pension company on behalf of qualifying employees. The pension cost charge represents contributions payable under the scheme by the charity to the private pension company. The charity has no liability under the scheme other than for the payment of those contributions.

q) Rentals payable under operating leases, where substantially all the risks and rewards of ownership remain with the lessor, are charged to the Statement of Financial Activities on a straight line basis over the lease duration.

r) The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value. Interest on funds held on deposit is included when receivable and the amount can be reliably measured by the charity; this is normally upon notification of the interest paid or payable by the bank.

Notes to the financial statements

For the year ended 30 June 2019

2. Legal status

The charity is a company limited by guarantee and a public benefit entity which has no share capital. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity.

3. Donations and legacies

	Unrestricted £	Restricted £	TOTAL 2019 £	TOTAL 2018 £
Legacies	231,041	500	231,541	181,170
Gifts from individuals and trusts	204,770	438,212	642,982	625,007
Donated services	555,707	0	555,707	405,703
General donations	1,317,732	1,121	1,318,853	1,127,172
Corporate donations	14,398	2,133	16,531	16,256
	2,323,648	441,966	2,765,614	2,355,308
Gifts in kind				
Professional services	11,548	0	11,548	7,425
Web advertising	47,759	0	47,759	49,638
Management expertise	0	0	0	4,740
Outdoor advertising space	404,000	0	404,000	282,900
Other advertising space	92,400	0	92,400	61,000
	555,707	0	555,707	405,703

	Unrestricted £	Restricted £	TOTAL 2018 £	TOTAL 2017 £
Legacies	179,670	1,500	181,170	195,758
Gifts from individuals and trusts	213,639	411,368	625,007	532,971
Donated services	405,703	0	405,703	222,641
General donations	1,091,815	35,357	1,127,172	912,029
Corporate donations	16,256	0	16,256	24,868
	1,907,083	448,225	2,355,308	1,888,267
Gifts in kind				
Professional services	7,425	0	7,425	1,500
Web advertising	49,638	0	49,638	35,422
Management expertise	4,740	0	4,740	5,419
Outdoor advertising space	282,900	0	282,900	180,300
Other advertising space	61,000	0	61,000	0
	405,703	0	405,703	222,641

Gifts in kind relate to the provision of professional and management services (£11,548), and publicity of our services to women with ovarian cancer (£544,159) provided at the estimable market rate. During the year, the charity received donations of web advertising space, magazine advertising, professional and management services and outdoor advertising services. The charity has benefited from the contribution of unpaid general volunteers which have not been identified in these accounts. No commitments or other unrecognised contingencies have arisen from these donations.

Notes to the financial statements

For the year ended 30 June 2019

4. Total expenditure

	Fundraising & publicity £	Research - medical £	Earlier diagnosis £	Supportive services £	TOTAL 2019 £	TOTAL 2018 £
Staff costs	364,575	115,265	151,002	265,842	896,684	774,791
Direct costs	192,154	8,598	41,275	80,724	322,751	415,526
Donated services	1,440	5,000	541,909	7,358	555,707	405,703
Advocacy	0	0	57,571	38,381	95,952	73,922
Medical grants	0	123,296	0	0	123,296	84,669
Support costs	163,633	51,735	67,774	119,318	402,460	381,317
TOTAL	721,802	303,894	859,531	511,623	2,396,850	2,135,928

The increase in directs costs and donated services reflect the success of the integrated campaign during the year.

	Fundraising & publicity £	Research - pathfinder £	Research - medical £	Earlier diagnosis £	Supportive services £	TOTAL 2018 £	TOTAL 2017 £
Staff costs	304,092	44,047	55,998	129,220	241,433	774,791	669,403
Direct costs	264,579	8,776	18,647	41,451	82,073	415,526	337,191
Donated services	12,165	0	0	393,538	0	405,703	222,641
Advocacy	0	0	0	44,353	29,569	73,922	57,910
Medical grants	0	0	84,669	0	0	84,669	114,750
Support costs	149,660	21,678	27,560	63,596	118,824	381,317	281,927
TOTAL	730,496	74,501	186,874	672,158	471,899	2,135,928	1,683,822

Analysis of support costs

	2019 £	2018 £
Staff costs	149,600	133,717
Governance costs	16,758	18,317
Office costs	223,183	208,306
Legal and professional	5,067	3,300
Depreciation	7,852	17,677
TOTAL	402,460	381,317

Support costs are allocated on the basis of the staff costs of each department.

The increase in staff costs reflects the appointment of a temporary Database Officer to deliver targeted support to our data management.

Analysis of advocacy costs

	2019 £	2018 £
Staff costs	75,747	61,895
Direct costs	20,205	12,027
TOTAL	95,952	73,922

Advocacy costs are allocated on the basis of the work performed.

Earlier diagnosis 60 per cent
Supportive services 40 per cent

Notes to the financial statements

For the year ended 30 June 2019

5. Net income for the year

This is stated after charging:	2019 £	2018 £
Depreciation	7,851	17,677
Operating lease rentals: property	86,155	74,515
Auditors' remuneration:	10,480	9,200
	104,486	101,392

No trustees reclaimed expenses in 2019 (2018 £0). No trustees have been paid any remuneration or received any other benefits from an employment or a related entity.

6. Staff costs and numbers

Staff costs were as follows:	2019 £	2018 £
Salaries and wages	954,599	829,979
Social security costs	94,877	84,666
Pensions	44,317	38,757
Consultancy	28,238	17,000
Total emoluments paid to staff were:	1,122,031	970,402

The key management personnel of the charity comprises of the Chief Executive, the Director of Finance and Corporate Services, the Director of Development, the Director of Public Affairs and Services, the Director of Communications and the Head of Information and Support. The total employee benefits of the key management personnel of the charity were £449,724 (2018: £429,482), an increase of 5 per cent. This includes the transition from maternity cover to a permanent role for one post.

One employee earned between £80,001 and £90,000 in 2019 (2018: One employee between £80,001 and £90,000). Pension costs relating to this employee amounted to £4,494 (2018: £4,494). One employee earned between £70,001 and £80,000 in 2019 (2018: No employees between £70,001 and £80,000). Two employees earned between £60,001 and £70,000 in 2019 (2018: One employee between £60,001 and £70,000).

6. Staff costs and numbers (cont.)

	2019 No.	2018 No.
Fundraising and publicity	9.2	9.2
Research	1.6	2.5
Supportive services	7.3	6.9
Earlier diagnosis	4.1	3.7
Advocacy	2.1	1.2
Governance	0.7	0.5
Support	2.2	1.5
	27.2	25.5

At 30 June 2019 the charity employed 28 staff (2018: 27 staff). The average number of staff in the year was 28 (2018: 23).

7. Grant making

	2019 £	2018 £
Research grants	123,296	84,669
Costs of managing the grant making programme	14,792	18,647

In 2018-19 the Scientific Advisory Board agreed to award the following medical research grants:

- (i) University of Glasgow, Professor Iain McNeish. Interleukin-6 as a therapeutic target in ovarian clear cell carcinoma. Year three funding £19,645.
- (ii) University of Surrey, Dr Agnieszka Michael. EDMOND. A feasibility study of elemental diet as an alternative to parenteral nutrition for ovarian cancer patients with inoperable malignant bowel obstruction. Year three funding £1,400.
- (iii) St Mary’s Hospital, Professor Richard Edmondson. Manchester - RE17 - Translating our knowledge of the DNA damage response into clinical benefits with patients with ovarian cancer. Year two funding £63,130.
- (iv) University of Cambridge, Dr Martin Miller. Unravelling the tumour-immune microenvironment for new ovarian cancer treatment strategies. Year one funding £57,166.

Notes to the financial statements

For the year ended 30 June 2019

8. Taxation

Target Ovarian Cancer is considered to pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2011 and, therefore, it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

9. Tangible fixed assets

Furniture, fixtures and equipment	2019 £	2018 £
Cost		
At the start of the year	182,639	162,486
Additions in the year	1,538	20,153
At the end of the year	184,177	182,639
Depreciation		
At the start of the year	164,191	146,514
Charge for the year	7,851	17,677
At the end of the year	172,042	164,191
Net book value		
At the end of the year	12,135	18,448
At the start of the year	18,448	15,972

10. Debtors

	2019 £	2018 £
Debtors control account	30,000	21,000
Prepayments	65,415	31,270
Other debtors	103,798	2,426
	199,213	54,696

11. Cash at bank and in hand

	2019 £	2018 £
Current accounts	969,108	771,009
Short term deposits	455,858	453,887
	1,424,966	1,224,896

12. Creditors and accruals

	Amounts due within one year	
	2019 £	2018 £
Trade creditors	109,224	128,792
Deferred income	27,000	-
Grants payable	160,461	200,588
Taxation and social security	26,625	26,288
Pension	-	11,236
Accrued expenditure	50,137	40,356
	373,447	407,260

There were no creditors due after one year.

Notes to the financial statements

For the year ended 30 June 2019

12. Creditors and accruals (cont.)

Deferred income	Amounts due within one year	
	2019 £	2018 £
Opening deferred income	81,000	38,434
Released in the accounting period	(54,000)	(38,434)
Deferred to future periods	27,000	-
Closing deferred income	27,000	-
Analysed as deferred income falling due		
Within one year		
	27,000	-
After one year		
	-	-
There was no deferred income for 2018, and consequently no prior year comparator. Following a review of historic pension records in 2019, where pension contributions were accrued, but pensions not taken up or deferred, £11,236 was released back in the year.		
Grants payable at 1 July 2018	200,588	
Grants awarded	123,297	
Grant payments made in year	(163,424)	
Total grants outstanding at 30 June 2019	160,461	

13. Financial Instruments

	2019 £	2018 £
Cash	1,424,966	1,224,896
Financial assets held at amortised cost	176,278	23,426
Financial liabilities held at amortised cost	(346,447)	(421,349)
Net financial assets	1,254,797	826,973

- a) Financial assets held at amortised cost included debtors, accrued income and other debtors but excludes prepayments.
- b) Financial liabilities held at amortised costs include trade creditors and all other creditors except deferred income and statutory taxes.

14. Analysis of net assets between funds

	Unrestricted funds £	Restricted funds £	Total funds £
2019			
Tangible fixed assets	12,135	-	12,135
Current assets	809,222	814,957	1,624,179
Current liabilities	(151,995)	(221,452)	(373,447)
Net assets at the end of the year	669,362	593,505	1,262,867
2018			
Tangible fixed assets	18,448	-	18,448
Current assets	624,055	655,536	1,279,591
Current liabilities	(175,041)	(232,218)	(407,259)
Net assets at the end of the year	467,462	423,318	890,780

Notes to the financial statements

For the year ended 30 June 2019

14. Analysis of net assets between funds (cont.)

Movements in funds 2019	At the start of the year £	Income £	Expenditure £	At the end of the year £
Restricted funds:				
(a) Supportive services	-	75,212	(75,212)	-
(b) Research programme	410,452	292,566	(166,079)	536,939
(c) Earlier diagnosis	-	30,488	(30,488)	-
(d) In touch	12,866	-	-	12,866
(e) Peter Sowerby Foundation	-	43,700	-	43,700
Total restricted funds	423,318	441,966	(271,779)	593,505
Total unrestricted funds	467,462	2,326,971	(2,125,071)	669,362
Total funds	890,780	2,768,937	(2,396,850)	1,262,867

Movements in funds 2018	At the start of the year £	Income £	Expenditure £	At the end of the year £
Restricted funds:				
(a) Supportive services	-	197,218	(197,218)	-
(b) Research programme	279,687	223,457	(92,692)	410,452
(c) Earlier diagnosis	-	27,550	(27,550)	-
(d) In touch	16,909	-	(4,043)	12,866
Total restricted funds	296,596	448,225	(321,503)	423,318
Total unrestricted funds	374,265	1,907,622	(1,814,425)	467,462
Total funds	670,861	2,355,847	(2,135,928)	890,780

Purpose of funds

(a) Supportive services	To provide information and support to women with ovarian cancer.
(b) Research programme	To fund research into aspects of ovarian cancer.
(c) Earlier diagnosis	To raise awareness of the symptoms of ovarian cancer.
(d) In touch	To provide support networks for women with ovarian cancer.
(e) Peter Sowerby Foundation	To identify and break down the barriers to the diagnosis of ovarian cancer.

15. Designated funds

It was agreed to designate the balance (£42,050) of the legacy received from Mr Gordon Luton of £157,750 to support the investment in legacy fundraising and the extension of the integrated campaign in order to secure a significant increase in income to deliver the growth plans. The funds are expected to be spent over the next year as follows:

Designation 1: Legacy fundraising

Designation 2: Integrated campaign

Schedule of spend	2019-20 £	2018-19 £
Legacy fundraising	42,050	40,600
Integrated campaign		42,400
	42,050	83,000

Movement in funds 2019	At start of year £	Income £	Expenditure £	Transfer £	At end of year £
Designation 1: Legacy fundraising	82,650	-	(82,650)	42,050	42,050
Designation 2: Integrated campaign	42,400	-	(42,400)	-	-
	125,050	-	(125,050)	42,050	42,050

Movement in funds 2018	At start of year £	Income £	Expenditure £	Transfer £	At end of year £
Designation 1: Legacy fundraising	32,700	-	(32,700)	82,650	82,650
Designation 2: Integrated campaign	-	-	-	42,400	42,400
	32,700	-	(32,700)	125,050	125,050

Notes to the financial statements

For the year ended 30 June 2019

16. Contingent liabilities

During the year 2016-17, the charity entered into a long term grant arrangement with St Mary’s Hospital, Manchester, awarding a grant of £198,414 over a 36-month period. Subject to a successful review of the annual objectives, the Scientific Advisory Board will award the Year three funding £68,660 for St Mary’s Hospital in 2019-20. During the year 2018-19, the charity entered into a long term grant arrangement with the University of Cambridge, awarding a grant of £199,546 over a 36-month period. Subject to a successful review of the annual objectives, the Scientific Advisory Board will award the Year two funding of the University of Cambridge £75,194 in 2019-20 and the Year three funding £67,185 in 2020-21. All grant funding is subject to annual review by the Scientific Advisory Board before each year of funding is released.

17. Commitments under operating leases

As at 30 June 2019, the charity had annual commitments under non-cancellable operating leases as set out below:

Schedule of spend	Land and buildings	
	2019 £	2018 £
0 - 1 years	36,004	76,851
2 - 5 years	-	36,004

18. Related party transactions

Donations from trustees and on their behalf of £239,455 (2018: £214,002) were received during 2019.

19. Reconciliation of net income/(expenditure) to net cash flow from operating activities

	2019 £	2018 £
Net income/(expenditure) (as per the statement of financial activities)	372,087	219,919
Adjustments for:		
Depreciation charges	7,851	17,677
Dividends, interest and rents from investment	(3,323)	(539)
(Increase)/decrease in debtors	(144,517)	(5,953)
Increase/(decrease) in creditors	(33,813)	(39,932)
Net cash provided by/(used in) operating activities	198,285	191,172

20. Analysis of cash at bank and in hand

	2019 £	2018 £
	1,424,966	1,224,896

21. Post balance sheet events

The charity opened a savings account with Flagstone Investment Management in July 2019 to take advantage of higher interest rates not generally available. The sum of £255,000 was deposited into the Flagstone platform account. The instant access CAF Gold account and the CAF platinum 30 day notice were subsequently closed.

The charity was awarded £250,000 from the Ardeola Charitable Trust to support the upgrade of its ICT infrastructure. The award is funded over two years, for the period 2019-21. Year one of the funding, £125,000, was received in July 2019.

Notes to the financial statements

For the year ended 30 June 2019

22. SOFA 2017-18 comparator

STATEMENT OF FINANCIAL ACTIVITIES		Charity number: 1125038			
(incorporating an income and expenditure account)		Company number: 6619981			
For the year ended 30 June 2018					
	Notes	Unrestricted £	Restricted £	2018 £	2017 £
Income from:					
Donations and legacies	3	1,907,083	448,225	2,355,308	1,888,267
Investment income		539	-	539	824
Total income		1,907,622	448,225	2,355,847	1,889,091
Expenditure on:					
Raising funds		730,496	-	730,496	553,099
<i>Charitable activities</i>					
Research		168,683	92,692	261,375	300,390
Earlier diagnosis		644,608	27,550	672,158	423,179
Supportive services		270,638	201,261	471,899	407,154
Total expenditure	4	1,814,425	321,503	2,135,928	1,683,822
Net income for the year	5	93,197	126,722	219,919	205,269
Funds brought forward		374,265	296,596	670,861	465,592
Total funds carried forward		467,462	423,318	890,780	670,861

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above.

Reference and administrative details

Target Ovarian Cancer

Registered charity number 1125038 (England and Wales) and SC042920 (Scotland).
A company limited by guarantee, registered in England and Wales (No. 6619981).

Trustees

- Emma Kane (Chair)
- Shona Spence (Treasurer)
- Joanna M. Barker MBE (appointed 21 Feb 2019)
- Alexandra Cran-McGreehin
- Margaret Chamberlain
- Andrew Harrison

Patrons

- Professor Sir Kenneth Calman PhD MD FRCS FRCP
- Dame Janet Gaymer DBE QC
- Sarah Greene
- Chief Executive**
Annwen Jones OBE
- Company Secretary**
Alexine Horsup

Governing document

Memorandum and Articles of Association, 13 June 2008.

New Articles of Association adopted by Special Resolution, 29 December 2011, as amended by Special Resolution, 21 November 2013 and 14 April 2016.

Registered office
2 Angel Gate
London
EC1V 2PT

www.targetovariancancer.org.uk
020 7923 5470
info@targetovariancancer.org.uk

Bankers

- CAF Bank Ltd
25 Kings Hill Avenue
Kings Hill
West Malling
ME19 4JQ
- Coutts & Co
440 Strand
London
WC2R 0QS
- Scottish Widows Bank
PO Box 12757
Edinburgh
EH3 8YJ
- Shawbrook Bank
Lutea House
Warley Hill Business Park
Great Warley
Brentwood
Essex
CM13 3BE

Auditor

Haysmacintyre LLP, Statutory Auditors
10 Queen Street Place
London
EC4R 1AG

Solicitor

Stone King LLP
Boundary House
91 Charterhouse Street
London
EC1M 6HR

Acknowledgements

The Board of Trustees wishes to acknowledge the following for their outstanding support of Target Ovarian Cancer during the past year:

Directors Emeritus

Lisa Attenborough
Sonya Branch

Patrons

Professor Sir Kenneth Calman PhD MD FRCS FRCP
Dame Janet Gaymer DBE QC
Sarah Greene

Celebrity Ambassadors

Susan Calman
Gaby Roslin

Target Ovarian Cancer Scientific Advisory Board

Professor Ruth Plummer (Chair), Professor of Experimental Cancer Medicine at the Northern Institute for Cancer Research, Newcastle University

Professor Richard Edmondson, Clinical Professor in Gynaecological Oncology, Manchester University

Dr Ros Glasspool, Chair of the ovarian cancer sub-group, National Cancer Research Institute, Consultant Medical Oncologist and Honorary Clinical Senior Lecturer, University of Glasgow

Professor Maurizio D’Incalci, Chief of the Laboratory of Cancer Chemotherapy and Chief of the Department of Oncology, the Mario Negri Institute of Milan

Dr Rebecca Kristeleit, Consultant Medical Oncologist, UCL Cancer Institute

Professor Peter L Stern PhD, Head of the Cancer Research UK Immunology Group, Paterson Institute for Cancer Research, University of Manchester

Target Ovarian Cancer General Practitioner Advisory Board

Professor Nigel Sparrow OBE (Chair), Senior National GP Adviser, Care Quality Commission

Jenny Aston QN, Advanced Nurse Practitioner and RCGP Nurse Champion

Dr Nina Craft, General Practitioner, Woodbrooke Medical Practice, Belfast

Dr Elise Lang, General Practitioner and Macmillan GP Cancer Lead for Velindre NHS Trust, Macmillan GP Adviser Wales

Dr Hilary Morrison, Patient representative

Dr Dirk Pilat, General Practitioner and Medical Director for e-Learning, Royal College of General Practitioners

Professor Debbie Sharp, Professor of Primary Health Care, University of Bristol

Dr Alison Wint, Clinical Lead for Cancer South Gloucester CCG and Macmillan GP, Montpelier Health, Pilning Surgery

Target Ovarian Cancer Clinical Advisory Panel

Dr Vicki Barber, GP, Kettering

Mr Janos Balega, Consultant Gynaecological Oncologist, Birmingham

Lynn Buckley, Clinical Nurse Specialist, Hull

Dr Alison Farmer, Psycho-oncology Nurse Specialist, Southampton

Professor Richard Edmondson, Professor of Gynaecological Oncology, Manchester

Professor Iain McNeish, Consultant Medical Oncologist, Glasgow

Dr Alex Murray, Consultant Clinical Geneticist, Cardiff

Dr Jennifer Pascoe, Medical Oncologist, Birmingham

Dr Marc Tischkowitz, Honorary Consultant, Department of Medical Genetics, Cambridge

Dr Sarah Williams, Consultant Medical Oncologist, Birmingham

Lisa Young, Clinical Nurse Specialist, Southampton

Target Ovarian Cancer Digital Advisory Panel

Amanda Cawthorn, patient representative

Sally Falvey, Head of Charity Marketing, JustGiving

David Glaser, Non-Executive Chair, Web Results Direct

Becki Golding, family member representative

Louise Horner, Head of Digital, Relevance Digital Marketing

Emile Kott, Director, AcroWeb

If you wish to donate to Target Ovarian Cancer,
please get in touch

Visit **www.targetovariancancer.org.uk** or call **020 7923 5470**

Symptoms of ovarian cancer

- Persistent bloating
- Feeling full quickly and/or loss of appetite
- Pelvic or abdominal pain (that's your tummy and below)
- Urinary symptoms (needing to wee more urgently or more often than usual)

Need someone to talk to about ovarian cancer? Contact our nurse-led Support Line

Phone: **020 7923 5475**

Website: **targetovariancancer.org.uk/supportline**